Luye Pharma Group Drug Meets Main Goal of Phase 2 Study

MT Newswires Live06-17

Luye Pharma Group (HKG:2186) said a mid-stage study of LY03015 in China met its main goal, according to a Tuesday filing with the Hong Kong bourse.

The firm was studying the drug as a treatment for tardive dyskinesia and chorea associated with Huntington's disease.

According to results from the phase 2 trial, subjects receiving the strongest dose of LY03015 reported a response rate of 76.5%, nearly double the historical data for current first-line drugs, the firm said.

Subjects also saw a "significant improvement" in symptoms and minimal rebound following treatment cessation.

Based on the results, the firm said it now plans to advance the drug into phase 3 clinical trials in both China and the U.S.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644790115?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 12:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644790115","market":"us","top_or_hot":-1,"title":"Luye Pharma Group Drug Meets Main Goal of Phase 2 Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LYPHF\">Luye Pharma</a> Group (HKG:2186) said a mid-stage study of LY03015 in China met its main goal, according to a Tuesday filing with the Hong Kong bourse.</p><p>The firm was studying the drug as a treatment for tardive dyskinesia and chorea associated with Huntington's disease.</p><p>According to results from the phase 2 trial, subjects receiving the strongest dose of LY03015 reported a response rate of 76.5%, nearly double the historical data for current first-line drugs, the firm said.</p><p>Subjects also saw a \"significant improvement\" in symptoms and minimal rebound following treatment cessation.</p><p>Based on the results, the firm said it now plans to advance the drug into phase 3 clinical trials in both China and the U.S.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Luye Pharma Group Drug Meets Main Goal of Phase 2 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLuye Pharma Group Drug Meets Main Goal of Phase 2 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-17 12:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LYPHF\">Luye Pharma</a> Group (HKG:2186) said a mid-stage study of LY03015 in China met its main goal, according to a Tuesday filing with the Hong Kong bourse.</p><p>The firm was studying the drug as a treatment for tardive dyskinesia and chorea associated with Huntington's disease.</p><p>According to results from the phase 2 trial, subjects receiving the strongest dose of LY03015 reported a response rate of 76.5%, nearly double the historical data for current first-line drugs, the firm said.</p><p>Subjects also saw a \"significant improvement\" in symptoms and minimal rebound following treatment cessation.</p><p>Based on the results, the firm said it now plans to advance the drug into phase 3 clinical trials in both China and the U.S.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644790115","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644790115","pubTimestamp":1781671397,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Luye Pharma Group  said a mid-stage study of LY03015 in China met its main goal, according to a Tuesday filing with the Hong Kong bourse.The firm was studying the drug as a treatment for tardive dyskinesia and chorea associated with Huntington's disease.According to results from the phase 2 trial, subjects receiving the strongest dose of LY03015 reported a response rate of 76.5%, nearly double the historical data for current first-line drugs, the firm said.Subjects also saw a \"significant improvement\" in symptoms and minimal rebound following treatment cessation.Based on the results, the firm said it now plans to advance the drug into phase 3 clinical trials in both China and the U.S.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","02186":"绿叶制药","BK1606":"中医药概念"},"translate_title":"绿叶制药集团药物达到2期研究主要目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":1},"content_text":"Luye Pharma Group (HKG:2186) said a mid-stage study of LY03015 in China met its main goal, according to a Tuesday filing with the Hong Kong bourse.The firm was studying the drug as a treatment for tardive dyskinesia and chorea associated with Huntington's disease.According to results from the phase 2 trial, subjects receiving the strongest dose of LY03015 reported a response rate of 76.5%, nearly double the historical data for current first-line drugs, the firm said.Subjects also saw a \"significant improvement\" in symptoms and minimal rebound following treatment cessation.Based on the results, the firm said it now plans to advance the drug into phase 3 clinical trials in both China and the U.S.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644790115","isCrawlerRequest":true}